My passion for Biotech began by pure chance. I was working as a Financial Analyst in the Investment Management Division of a large US Investment Bank when the bank's research department released a "Biotech 101" research piece. The report gave an introduction to the sector, including the underlying science and the regulatory aspects, and I was fascinated every since. Even though my background is not in science, I greatly enjoy researching a company's pipeline, the efficiacy of their drugs, and their prospects in the financial markets - and of course how to profit from those catalysts, either as outright purchases or through option-based approaches. In my research, I focus on biotech companies that find themselves in "special situations" (such as mergers or spin-offs) as well as those companies that are not your normal biotech (such as with unusual business models or revenue streams). I firmly believe that biotech will continue to be a sector in which investors can realize outstanding returns through diligent research, but that biotech will also be a sector in which we will see truly groundbreaking research over the next decade. One of my favorite stories was bluebird bio's publication of the results of its CAR-T multiple myeloma therapy, after which patients with no other therapeutic options went into complete remission. I'm certain that scientific progress will only go further from here.